MR-39
MR-39 is a FPR2 agonist (EC50 = 3.9 μM). MR-39 activates FPR2 to promote neuroinflammation resolution (downregulates IL-1β and TNF-α, modulates NF-κB), upregulates synaptic proteins (synaptic proteins) and improves dendritic spine morphology. MR-39 inhibits MAPK/ERK and AKT phosphorylation in glioblastoma, induces S-phase arrest, and suppresses migration, angiogenesis, and hypoxic adaptation. MR-39 reduces Aβ plaque burden via inhibiting MyD88/NF-κB and NLRP3 inflammasome. MR-39 can be used for research on autism spectrum disorder, Alzheimer's disease, and glioblastoma.
For research use only. We do not sell to patients.
- CAS No.: 2169267-60-9
- Formula: C27H23ClF2N4O2
- Molecular Weight:508.95
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
All Caspase Isoforms
More
Biological Activity
Description
|
HIF-1α |
Caspase-1 |
IL-10 |
IL-4 |
IL-1β |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| U-87MG ATCC | IC50 |
12.56 μM
|
Dose-dependent antiproliferative activity against U87-MG cells.
Dose-dependent antiproliferative activity against U87-MG cells.
|
41652630 |
| U138-MG | IC50 |
12.82 μM
|
Dose-dependent antiproliferative activity against U138-MG cells
Dose-dependent antiproliferative activity against U138-MG cells
|
41652630 |
| U-251 | IC50 |
9.75 μM
|
Dose-dependent antiproliferative activity against U251-MG cells
Dose-dependent antiproliferative activity against U251-MG cells
|
41652630 |
In Vitro
MR-39 (10 μM) shows low-to-moderate interactions with cannabinoid CB1/CB2 receptors (55% displacement), DAT (87% displacement), 5-HT₂B receptor (59% displacement), and L-type calcium channel (84% displacement) in the Mini Safety 44 Panel, while showing no significant interaction with the remaining targets[1].
MR-39 (0.1-10 μM) inhibits hERG (IC50= 1.98 μM), hNav1.5 (IC50= 4.74 μM), and hCav1.2 (IC50= 0.68 μM) ion channels in HEK-293 cells, suggesting potential cardiotoxicity risk[1].
MR-39 (0.04-100 μM; 72 h) exhibits cytotoxicity in HepG2 cells with an AC50 of 0.625 μM, indicating low-to-moderate hepatotoxicity[1].
MR-39 (7.81-250 μg/mL; 90 min exposure, followed by 48 h culture) shows no genotoxicity in Salmonella TA98 and TA100 strains (Ames test)[1].
MR-39 is stable in plasma (t1/2 = 371, 932, and 1200 min in mouse, monkey, and human, respectively), shows a t1/2 of 64 min in human liver microsomes, but is metabolized rapidly in hepatocytes (t1/2 = 12.7, 14.8, and 26.6 min in mouse, monkey, and human, respectively), suggesting that non-CYP pathways may predominate; it exhibits high plasma protein binding (>92%) and blood-to-plasma ratios of 0.776, 0.906, 0.628, and 0.739 in mouse, rat, dog, and human, respectively, indicating that it distributes mainly in plasma[1].
MR-39 (3 μM; 60 min) shows moderate permeability in Caco-2 cell monolayers, with Papp AB (apical-to-basal) of 0.669×10-6 cm/s and Papp BA (basal-to-apical) of 8.2×10-6 cm/s, and an efflux ratio (ER) of 12.3, indicating significant efflux activity; in the presence of the P-gp inhibitor Verapamil (HY-14275), AB increases to 2.42, BA decreases to 5.29, and ER drops to 2.19; in the presence of the BCRP inhibitor Fumitremorgin C (HY-N2143), AB increases to 1.91, BA decreases to 9.19, and ER drops to 4.81. These results indicate that MR-39 interacts with both P-gp and BCRP, with a stronger interaction with P-gp than with BCRP[1].
The antiproliferative effects of MR-39 on glioblastoma cells and its neuroprotective effects against Aβ1-42-induced neuroinflammation in hippocampal organotypic cultures are both blocked by the FPR2 antagonist WRW4 (HY-P1119) and are absent in FPR2 knockout cultures, indicating that its effects are FPR2-dependent[2][4].
MR-39 (5-100 μM; 48 h) shows dose-dependent antiproliferative activity against human glioblastoma cells, with IC50values of 12.56 μM (U87-MG), 12.82 μM (U138-MG), and 9.75 μM (U251-MG)[2].
MR-39 (10 μM; 48 h) reduces Ki67 expression, inhibits MAPK/ERK and AKT phosphorylation, and induces non-canonical p53-dependent S-phase arrest (with CCND2 mRNA upregulation, CDK1 mRNA downregulation, p53 protein upregulation, and p27 protein downregulation, while p21 remains unchanged) in U87-MG and U138-MG cells[2].
MR-39 (10 μM; 48 h) downregulates gene pathways related to migration/invasion, angiogenesis, and hypoxia response in U87-MG cells, as shown by RNA-seq and RT-qPCR[2].
MR-39 (10 μM; 48 h) upregulates E-cadherin and downregulates N-cadherin, Slug, Snail, MMP-2, FN1, CPA4, VEGF, and VE-cadherin mRNA expression in U87-MG and U138-MG cells, and reduces FN1 and VEGF protein levels in U87-MG cells[2].
MR-39 (10 μM; 24-72 h) inhibits cell migration (approximately 20% inhibition) in U138-MG and U251-MG cells as shown by wound healing assay[2].
MR-39 (10 μM; 48 h) inhibits in vitro angiogenesis (reducing loop formation, loop area, and loop perimeter by approximately 50%) in EA.hy926 endothelial cells[2].
MR-39 (10 μM; 48 h) significantly reduces HIF-1α mRNA and protein expression under CoCl₂-induced chemical hypoxia and enhances the antiproliferative effect in U87-MG cells[2].
MR-39 reduces NF-κB protein levels in glioblastoma cells and inhibits NF-κB phosphorylation in hippocampal organotypic cultures, indicating that it regulates the NF-κB inflammatory signaling pathway[2][4].
MR-39 downregulates pro-inflammatory cytokines IL-1β and TNF-α expression in both U87-MG and U138-MG glioblastoma cells and in WT mouse hippocampal organotypic cultures[2][4].
MR-39 (10 μM; 48 h) downregulates pro-inflammatory genes COX-2, CXCL-7, NFKB1, and IL-6 mRNA expression in U87-MG and U138-MG cells[2].
MR-39 (1 μM; pretreated for 1 h, followed by 24 h stimulation) inhibits Aβ1-42-induced MyD88 synthesis, NF-κB phosphorylation, and increases in NLRP3, Caspase-1, and ASC protein levels via an FPR2-dependent mechanism in WT mouse hippocampal organotypic cultures[4].
MR-39 (1 μM; pretreated for 1 h, followed by 24 h stimulation) reduces Aβ1-42-induced LDH release, increases anti-inflammatory IL-4 release (but decreases IL-10 levels; Aβ1-42 alone has no effect on IL-10 in WT cultures), and shows no significant effect on NO release via an FPR2-dependent mechanism in WT mouse hippocampal organotypic cultures[4].
MR-39 (10 μM; 4 h and 72 h) significantly stimulates neurite elongation in primary hippocampal neurons from BTBR mice, restoring neurite length to B6 control levels, while showing no significant effect on hippocampal neurons from B6 mice[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:HepG2 cells
-
Concentration:0.04, 0.1, 0.4, 1, 4, 10, 40 and 100 μM
-
Incubation Time:72 h
-
Result:Showed cytotoxic effects with an AC50 of 0.625 μM, indicating low to moderate hepatotoxicity.
-
Cell Line:U87-MG, U138-MG, U251-MG cells
-
Concentration:5, 7.5, 10, 25, 50 and 100 μM (dose-response); 10 µM (subsequent experiments)
-
Incubation Time:48 h
-
Result:Showed dose-dependent antiproliferative activity in all three cell lines, with IC50values of 12.56 µM (U87-MG), 12.82 µM (U138-MG), and 9.75 µM (U251-MG). The effect was reversed by the FPR2 antagonist WRW4 (10 µM) and by FPR2 siRNA silencing.
-
Cell Line:U87-MG, U138-MG, U251-MG cells
-
Concentration:10 µM
-
Incubation Time:48 h
-
Result:Showed no decrease in cell viability, indicating that the antiproliferative effect was cytostatic rather than cytotoxic.
-
Cell Line:U87-MG cells
-
Concentration:10 µM
-
Incubation Time:48 h
-
Result:Reduced ERK1/2 phosphorylation by approximately 70% and AKT phosphorylation by approximately 50%. Decreased FN1, VEGF, and NF-κB protein levels. Increased p53 protein levels, decreased p27 protein levels, while p21 protein levels remained unchanged.
-
Cell Line:U87-MG, U138-MG cells
-
Concentration:10 µM
-
Incubation Time:48 h
-
Result:Induced S-phase accumulation and reduced G2/M-phase population. The effect was reversed by WRW4 (10 µM) co-treatment.
-
Cell Line:U87-MG, U138-MG cells
-
Concentration:10 µM
-
Incubation Time:48 h
-
Result:Significantly reduced Ki67 expression in both cell lines, confirming decreased cell proliferation.
-
Cell Line:U87-MG cells
-
Concentration:10 µM (with 100 µM CoCl₂ for hypoxia induction)
-
Incubation Time:48 h
-
Result:Under CoCl₂-induced hypoxic conditions, reduced HIF-1α protein expression, while showing no effect on HIF-1α under normoxic conditions.
-
Cell Line:U87-MG, U138-MG cells
-
Concentration:10 µM
-
Incubation Time:48 h
-
Result:Increased CCND2 mRNA and decreased CDK1 mRNA levels. Upregulated E-cadherin; downregulated N-cadherin, Slug, Snail, MMP-2, FN1, CPA4, VEGF, and VE-cadherin mRNA levels. Downregulated HIF-1α mRNA under hypoxic conditions. Downregulated COX-2, CXCL-7, NFKB1, IL-1β, and IL-6 mRNA levels. Similar trends were observed in U138-MG cells.
-
Cell Line:U138-MG, U251-MG cells
-
Concentration:10 µM
-
Incubation Time:Monitored at 0, 24, 48, and 72 h
-
Result:Significantly inhibited gap closure by approximately 20%, an effect reversed by WRW4 (10 µM) co-treatment. Similar results were obtained in U251-MG cells.
-
Cell Line:WT and FPR2 KO mouse hippocampal organotypic cultures
-
Concentration:1 µM (MR-39); 10 µM (fibrillar Aβ1-42)
-
Incubation Time:Pretreated with MR-39 for 1 h, followed by co-stimulation with Aβ1-42 for 24 h
-
Result:Reduced Aβ1-42-induced LDH release in WT cultures, while showing no effect in FPR2 KO cultures. The effect was blocked by the FPR2 antagonist WRW4 (10 µM).
-
Cell Line:WT and FPR2 KO mouse hippocampal organotypic cultures
-
Concentration:1 µM (MR-39); 10 µM (fibrillar Aβ1-42); 10 µM (WRW4)
-
Incubation Time:Pretreated with MR-39 for 1 h, followed by co-stimulation with Aβ1-42 for 24 h
-
Result:Decreased pro-inflammatory cytokines IL-1β and TNF-α levels in WT cultures (but showed no effect on IL-6). Increased anti-inflammatory IL-4 release but decreased IL-10 levels in WT cultures. Inhibited MyD88 synthesis, NF-κB phosphorylation, and NLRP3, Caspase-1, and ASC protein levels in WT cultures. All effects were blocked by WRW4 and absent in FPR2 KO cultures.
Parmacokinetics
| Species | Dose | Route | Tmax | Cmax |
|---|---|---|---|---|
| Mice[1] | 10 mg/kg | i.p. | 1 h | 813 ng/mL |
In Vivo
MR-39 (10 mg/kg; i.p.; once daily; for 14 consecutive days) shows favorable in vivo safety in C57BL/6NCRL mice, with no drug accumulation or treatment-related toxicity observed[1].
MR-39 (10 mg/kg; i.p.; once daily; for 8 days) restores hippocampal LXA4 levels, upregulates FPR2 mRNA expression (with protein levels also upregulated in BTBR mice), reduces pro-inflammatory Tnf-α and Il-1β mRNA levels, increases anti-inflammatory IL-10 mRNA levels, and significantly improves social behavior and reduces self-grooming in both BTBR and VPA mouse models of ASD[3].
MR-39 (10 mg/kg; i.p.; twice a week; for 20 weeks) improves cortical neuronal survival, reduces cortical microglial density and hippocampal Aβ plaque area, but shows no significant effects on hippocampal neurons, hippocampal microglia, or astrocytes in APP/PS1 mouse models[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:
-
Dosage:10 mg/kg
-
Administration:Intraperitoneal injection (i.p.), once daily for 8 consecutive days
-
Result:Significantly reduced IL-1β and TNF-α mRNA levels in both hippocampus and cortex. Did not restore NF-κB mRNA levels in either region, but rescued decreased NF-κB protein in the hippocampus and increased it in the cortex, as measured by qPCR and Western blot.
Restored decreased hippocampal LXA4 levels to B6 levels. Significantly increased FPR2 mRNA and protein expression in the hippocampus, as determined by ELISA, RT-qPCR, and Western blot.
Decreased synaptophysin mRNA levels but significantly upregulated its protein levels in both hippocampus and cortex. Restored SYNPO mRNA and protein in the hippocampus.
Showed no effect on VAMP-2 mRNA or on PSD95 and synaptotagmin protein levels in either brain region.
In ex vivo cortical slices, selectively modulated spine morphology without altering spine density. Increased mushroom spine density and thin spine length in B6 mice, while reducing thin spine length and mushroom spine head diameter in BTBR mice, normalizing these features toward B6 levels.
In the three-chambered social test, significantly increased the time spent in the chamber with the novel mouse compared to the novel object, indicating improved sociability.
In the reciprocal social interaction test, significantly increased the number of following, push-crawl, nose-to-nose, and nose-to-anogenital sniffing bouts compared to BTBR-vehicle group.
Significantly decreased self-grooming behavior during social interaction, but did not rescue self-grooming when the mouse was alone in the cage, suggesting the effect depends on social context.
-
Animal Model:Male C57BL/6NCRL mice[1].
-
Dosage:10 mg/kg
-
Administration:Intraperitoneal injection (i.p.), once daily for 14 consecutive days
-
Result:Showed no clinical signs attributable to treatment-related toxicity throughout the study.
Body weight gains remained within the normal physiological range for age- and strain-matched mice.
Plasma and brain concentrations at 24 h after the last dose were both below LOQ, indicating no significant tissue accumulation.
-
Animal Model:Pregnant mice received a single intraperitoneal injection of valproic acid (VPA) at 500 mg/kg on gestational day 12.5 (GD 12.5), and 3-month-old male offspring were used for the experiment[3].
-
Dosage:10 mg/kg
-
Administration:Intraperitoneal injection (i.p.), once daily for 8 consecutive days
-
Result:Significantly increased the decreased hippocampal LXA4 level in VPA mice, as measured by ELISA.
Significantly increased hippocampal FPR2 mRNA expression, but did not significantly change FPR2 protein expression.
Significantly reduced hippocampal mRNA levels of pro-inflammatory cytokines Tnf-αand Il-1β.
Significantly increased hippocampal mRNA levels of anti-inflammatory cytokine IL-10.
In the three-chambered social test, significantly increased the time spent in the chamber with the novel mouse compared to the chamber with the novel object, indicating improved sociability.
In the reciprocal social interaction test, significantly increased the number of following and nose-to-nose sniffing bouts, and significantly decreased the time spent in self-grooming compared to VPA-vehicle group.
As for BTBR mice, the self-grooming behavior was only reduced during social interaction, not when the mouse was alone, confirming that social context is critical for the MR-39 rescuing effect on stereotyped behavior.
-
Animal Model:8-week-old male APP/PS1 double-transgenic mice co-expressing the human APP Swedish mutation and the human PS1 exon 9 deletion mutation. WT n = 12, WT + MR39 n = 5, APP/PS1 n = 10, APP/PS1 + MR39 n = 6[4].
-
Dosage:10 mg/kg
-
Administration:Intraperitoneal injection (i.p.), twice a week for 20 consecutive weeks (from 8 weeks to 29 weeks of age)
-
Result:Improved neuronal survival in the cortex (layer V) of APP/PS1 mice as shown by increased NeuN⁺ cell density.
Significantly reduced microglial cell density in the cortex of APP/PS1 mice, but showed no significant effect on microglial density in the hippocampus.
Showed no effect on astrocyte reactivity (GFAP⁺ staining) in the hippocampus of APP/PS1 mice.
Significantly reduced total Aβ plaque area in the hippocampus of APP/PS1 mice.
Showed no significant effect on the average number of Aβ plaques per area.
Showed no significant effect on the number of plaques across any size category.
Chemical Information
-
CAS No. 2169267-60-9
-
Molecular Weight 508.95
-
Formula C27H23ClF2N4O2
-
SMILES
FC1=CC=C(NC(N[C@@H](CC2=CC=C(C#N)C=C2)C(NCC3(CC3)C4=CC(Cl)=C(F)C=C4)=O)=O)C=C1
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Kinase activity and phosphorylation assays
Kinase activity assays measure the ability of kinases to transfer phosphate groups from ATP to specific substrates, while phosphorylation assays detect the presence and levels of phosphorylated proteins. Common methods include radiolabeled ATP incorporation (e. g. ,), ADP release detection via bioluminescence (e. g. ,[3]), enzyme-linked immunosorbent assays (ELISA) for phospho-specific epitopes (e. g. ,[6]), and microtiter-based formats for high-throughput screening (e. g. ,[8]). The ADP-Glo assay quantifies kinase activity by measuring ADP produced during phosphorylation using a luciferase-based system. Radiometric assays involve autoradiography or scintillation counting after incorporation of 32P-labeled ATP into substrate proteins. ELISA-based approaches rely on phospho-specific antibodies to detect activated kinases in cell lysates or purified samples.
-
Western Blot
Western blotting (WB) is a commonly used experimental method in molecular biology, biochemistry, and immunogenetics for identifying and quantifying target proteins. It combines gel electrophoresis with immunoassay, enabling researchers to analyze protein expression, post-translational modifications, and molecular weight.
-
Human pluripotent stem cell endothelial-cell differentiation
Human pluripotent stem cell endothelial differentiation is based on stepwise developmental patterning: early activation of WNT/GSK3β inhibition promotes mesodermal or vascular progenitor entry, followed by endothelial specification using VEGF-related signaling, BMP4, FGF2, Notch modulation, or cAMP depending on the published protocol. Endothelial differentiation is read out by acquisition of CD31, CD34, VE-cadherin/CD144, KDR/VEGFR2, vWF, Tie2, NOS3, acetylated LDL uptake, tube/network formation, barrier function, and in vivo vessel-forming capacity where tested.
-
Vascular/Branching Fractal Analysis
Vascular/branching fractal analysis quantifies the geometric complexity of vessel trees or vascular networks from segmented 2D images, commonly by converting vessels into binary and/or skeletonized maps and estimating fractal dimension using box-counting or related approaches. Fractal dimension is interpreted as an image-derived readout of vascular branching complexity, space filling, or density, and has been applied to retinal photographs, fluorescein angiography, OCT angiography, capillary perfusion maps, and in vitro Matrigel angiogenesis networks. The assay readout is generated from vessel-positive pixels after image preprocessing, vessel segmentation, binarization, and optional skeletonization; reported outputs include fractal dimension, vessel density, branchpoint density, endpoint density, vessel length density, tortuosity, and generation-based branching metrics when VESGEN-style analysis is used. The biological interpretation is limited to quantitative vascular patterning and s
-
Cell migration
Cell migration is a method that plays an important role in wound healing, cell differentiation, embryonic development, etc.
-
Endothelial Tube Formation Assay
Endothelial tube formation assay evaluates the ability of endothelial cells to attach, migrate, align, and organize into capillary-like networks when cultured on gelled basement membrane extract or Matrigel; the readout is the morphology and quantity of tube-like networks, which reflects an in vitro endothelial morphogenesis step related to angiogenesis. Basement membrane extract/Matrigel provides laminin-rich extracellular matrix cues that support endothelial differentiation into capillary-like structures, but it can contain biologically active growth factors, so growth-factor-reduced matrix is preferred when testing defined angiogenic stimulators or inhibitors.
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
-
Protocol for Kinase activity and phosphorylation assays
Kinase activity assays measure transfer of phosphate from ATP to a protein or peptide substrate, generating phosphorylated substrate, ADP, or incorporated radiolabeled phosphate as the readout; phosphorylation assays measure site-specific phosphorylation in cells or tissues as a proxy for kinase-pathway activation, inhibition, or substrate regulation. Phosphorylation can be detected by phospho-specific Western blot, immunoprecipitation kinase assay, phospho-immunofluorescence, phospho-flow cytometry, luminescent ADP detection, radiolabeled ATP incorporation, or reporter-based pathway assays, and these readouts can be applied to cancer cells, primary neurons, mouse tumors, organoids, inflammatory macrophages, ferroptosis studies, and mitophagy studies when the kinase target is biologically relevant.
-
Research Protocol for Neurological Diseases
PINK1/Parkin-mediated mitophagy pathway is a mitochondrial quality-control signaling axis in which mitochondrial depolarization stabilizes PINK1 on damaged mitochondria, activates Parkin recruitment and E3 ubiquitin ligase activity, promotes ubiquitination of outer mitochondrial membrane proteins, recruits selective autophagy adaptors, and drives lysosomal degradation of damaged mitochondria. In neurological disease research, this pathway is experimentally important because neurons, especially dopaminergic neurons, are highly dependent on mitochondrial integrity, and defective mitochondrial turnover can lead to mitochondrial dysfunction, oxidative stress, impaired neuronal survival, α-synuclein accumulation, and neuroinflammatory damage-associated signals. The genetic disease link is strongest in Parkinson’s disease because mutations in PRKN/parkin cause autosomal recessive juvenile parkinsonism, mutations in PINK1 cause hereditary early-onset Parkinson’s disease, and Drosophila studie
-
Endothelial Cell Migration/Angiogenic Sprouting Assay
Endothelial cell migration and angiogenic sprouting assays are in vitro (and partially ex vivo-adapted) functional models that quantify the ability of endothelial cells to undergo coordinated migration, extracellular matrix invasion, and multicellular organization into capillary-like sprouts in response to pro-angiogenic stimuli such as VEGF, bFGF, or conditioned microenvironments. These assays are used to model early angiogenic events including tip-cell formation, directional migration, and lumen-like sprout extension, which collectively reflect angiogenic activation and vascular morphogenesis processes observed in vivo.
-
Pyroptosis Solutions
Pyroptosis is a lytic inflammatory cell-death pathway executed by gasdermin pores, most classically through inflammasome-mediated activation of caspase-1, cleavage of gasdermin D, membrane pore formation, LDH release, and secretion of IL-1β and IL-18. The canonical pathway is commonly modeled by priming cells with an inflammatory signal such as LPS to induce pro-IL-1β and inflammasome components, followed by an activation signal such as ATP or nigericin to activate NLRP3, ASC speck formation, caspase-1 cleavage, GSDMD cleavage, cytokine release, and pyroptotic membrane rupture. The non-canonical pathway is triggered when cytosolic LPS activates mouse caspase-11 or human caspase-4/5, leading to GSDMD cleavage and pyroptosis, and this can secondarily activate NLRP3-dependent IL-1β release. Pyroptosis is linked to inflammatory injury, infection, cancer, liver disease, ocular disease, placental inflammation, and other disease phenotypes, but unresolved questions include which gasdermin fam
-
Alzheimer’s Disease Modeling
Alzheimer’s Disease (AD) is a neurodegenerative disorder characterized by a progressive decline in cognitive functions and loss of specific types of neurons and synapses. Alzheimer's symptoms can be simulated in mice by injecting drugs (such as Aβ) or genetically modified.
Purity & Documentation
References
[2]. Ferraro MG, et al. Formyl peptide receptor 2 activation by MR-39 inhibits glioblastoma cell proliferation and invasiveness through suppression of multiple oncogenic pathways. J Transl Med. 2026 Feb 6;24(1):342. [Content Brief]
[3]. Cristiano C, et al. Behavioral, Anti-Inflammatory, and Neuroprotective Effects of a Novel FPR2 Agonist in Two Mouse Models of Autism. Pharmaceuticals (Basel). 2022 Jan 28;15(2):161. [Content Brief]
[4]. Trojan E, et al. The N-Formyl Peptide Receptor 2 (FPR2) Agonist MR-39 Improves Ex Vivo and In Vivo Amyloid Beta (1-42)-Induced Neuroinflammation in Mouse Models of Alzheimer's Disease. Mol Neurobiol. 2021 Dec;58(12):6203-6221. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Keywords
- MR-39
- 2169267-60-9
- MR39
- MR 39
- Synaptic Vesicle Proteins
- NF-κB
- ERK
- Akt
- HIF/HIF Prolyl-Hydroxylase
- Interleukin Related
- MyD88
- TNF Receptor
- Caspase
- Formyl Peptide Receptor (FPR)
- FPR2 agonist
- MAPK/ERK inhibition
- AKT inhibition
- synaptic proteins
- synaptophysin
- synaptopodin
- Autism Spectrum Disorder
- dendritic spine morphology
- BTBR T+ tf/J mouse
- C57BL/6NCRL mouse
- autism spectrum disorder
- hippocampus
- cortex
- IL-1β
- TNF-α
- HepG2 cells
- HEK-293 cells
- Caco-2 cells
- hERG
- hNav1.5
- hCav1.2
- U87-MG
- U138-MG
- U251-MG
- EA.hy926
- brain tumor
- MAPK/ERK
- AKT
- Ki67
- CCND2
- CDK1
- p53
- p27
- p21
- E-cadherin
- N-cadherin
- Slug
- Snail
- MMP-2
- FN1
- CPA4
- VEGF
- VE-cadherin
- HIF-1α
- COX-2
- CXCL-7
- NFKB1
- IL-6
- LXA4
- FPR2
- IL10
- Alzheimer's disease
- Inhibitor
- inhibitor
- inhibit